Paper Details

  1. Home
  2. Paper Details

Tapentadol extended release in the management of peripheral diabetic neuropathic pain.

Author: BergerJack M, KaiAlice, KodumudiGopal, LeglerAron, MaslinBenjamin, VadiveluNalini

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review highlights the mechanisms of action and clinical efficacy of tapentadol, a μ-opioid agonist and norepinephrine reuptake inhibitor, particularly in the management of painful diabetic neuropathy. Tapentadol has shown effectiveness in treating various chronic pain conditions, including back pain, cancer-related pain, and arthritic pain, with fewer gastrointestinal side effects compared to traditional opioids. It has also been demonstrated to be effective in managing painful diabetic neuropathy.
Paper Details　
Original Abstract of the Article :
Tapentadol, a μ-opioid agonist and norepinephrine reuptake inhibitor, has been found to be an effective medication for a wide variety of chronic pain conditions, including back pain, cancer-related pain, and arthritic pain. It has also been found to have fewer gastrointestinal side effects than more...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298300/

データ提供：米国国立医学図書館（NLM）

Tapentadol Extended Release: A Treatment for Painful Diabetic Neuropathy

Painful diabetic neuropathy, a debilitating condition affecting many individuals with diabetes, is a significant challenge in pain management. This review examines the effectiveness of tapentadol extended release, a μ-opioid agonist and norepinephrine reuptake inhibitor, in managing this type of pain. The review summarizes the mechanisms of action of tapentadol and its clinical efficacy, particularly in treating painful diabetic neuropathy. The review highlights the potential of tapentadol extended release as a safe and effective treatment option for patients with this condition, particularly its reduced gastrointestinal side effects compared to traditional opioid-based therapies.

Tapentadol Extended Release: A Promising Treatment for Neuropathic Pain

The review's findings suggest that tapentadol extended release is a promising treatment for painful diabetic neuropathy. The drug's dual mechanism of action, targeting both opioid receptors and norepinephrine reuptake, coupled with its favorable safety profile, make it a valuable option for managing this challenging type of pain.

Managing Painful Diabetic Neuropathy

Painful diabetic neuropathy can significantly impact a person's quality of life. This review provides valuable information about tapentadol extended release as a potential treatment option for this condition. By understanding the drug's mechanisms and efficacy, patients and their doctors can make informed decisions about pain management.

Dr.Camel's Conclusion

This research is like finding a hidden spring of relief in the harsh desert of diabetic neuropathy! It highlights the potential of tapentadol extended release to provide effective and well-tolerated pain management for those suffering from this debilitating condition. This review offers a beacon of hope for those seeking better ways to control their neuropathic pain.

Date :
  1. Date Completed 2015-01-22
  2. Date Revised 2020-10-01
Further Info :

Pubmed ID

25609974

DOI: Digital Object Identifier

PMC4298300

Related Literature

Article Analysis
・Side Effects of tapentadol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.